Sequential Epirubicin-Docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. - Bianco,A.R.; De Matteis,A.; Manzione,L.; Boni,C.; Palazzo,S.; Di Palma,M.; Iacono,C.; De Placido,S.; Papaldo,P.; Cognetti,F. (J Clin Oncol, 2006)